46 results about "Isoprostaglandin E1" patented technology

A nano-emulsion injection of prostaglandin E1 contains the nano-emulsion particles of rostaglandin E1, the oil for injection, hydrophilic emulsifier, lipophilic emulsifier, isotonic agent, and stabilizer. Its preparing process and its quality control method are also disclosed.

An emulsion composition includes prostaglandin E1 (PGE1), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE1. Embodiments of the emulsion composition include an effective amount of PGE1, about 1% to about 30% (w / w) of a pharmaceutically acceptable oil as an oil base based on the weight of the emulsion composition, about 1% to about 30% (w / w) of a phospholipid with a high purity based on the weight of the oil base, about 1.6% to about 40% (w / w) of a non-proton-providing surfactant based on the weight of the oil base, and the balance of the emulsion composition being water.

A method is provided of determining whether an individual has reduced ability to form platelet thrombi. An ADP platelet activator and one or platelet inhibitors are provided. At least one of the platelet inhibitors is Prostaglandin E1 (PGE1). An alternate signal transduction pathway is produced. A final concentration of ADP is 2 to 35 μM and a final concentration of PGE1 is 2 to 30 nM, preferably 20 to 25 nM.

The invention relates to a method for preparing a prostaglandin E1 lipid microsphere injection of a charging non-homogeneous phase (comprising a water phase, an oil / water interfacial film phase and an oil phase) dispersion system, of which the surface of the lipid microsphere can be charged with positive electricity or negative electricity. The prostaglandin E1 is alprostadil, of which the chemical structure comprises a basic skeleton of 20-carbon fatty acid with a 5-carbon ring and two side chains, wherein one side chain is provided with a hydrophilic carboxylic acid group, so that the prostaglandin E1 has the characteristic of light surface activity action. By utilizing the characteristic, and according to the formula and the preparation process provided in the invention, the prostaglandin E1 has an unique drug-carrying mode in a solution of lipid microsphere with the non-homogeneous phase dispersion system, and the prepared lipid microsphere injection is fundamentally different from an alprostadil injection(Kaishi<TM>, and is prepared by adopting the technology of the Japanese business corporation LTT Bio-Pharma Co., Ltd. already sold in markets, and the difference lies in thatthe drug-carrying mode is completely different, the content of degradation products in the preparation such as impurities is more than 50 percent lower than that of in the Kaishi, so that the prostaglandin E1 lipid microsphere injection and the alprostadil injection are fundamentally different. The invention relates to a method for preparing the prostaglandin E1 lipid microsphere injection and the drug-carrying characteristics thereof in a three-phase system; in the formula, 0.0001 to 0.1 weight portion of prostaglandin E1 is used as a drug, the prostaglandin E1 is added with auxiliary materials for medical purpose to prepare the prostaglandin E1 lipid microsphere injection, and the auxiliary materials for medical purpose comprises the following materials in portion by weight: 5 to 20.

A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb / IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb / IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

An emulsion composition includes prostaglandin E 1 (PGE 1 ), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE 1 . Embodiments of the emulsion composition include an effective amount of PGE 1 , about 1 % to about 30% (w / w) of a pharmaceutically acceptable oil as an oil base based on the weight of the emulsion composition, about 1% to about 30% (w / w) of a phospholipid with a high purity based on the weight of the oil base, about 1.6% to about 40% (w / w) of a non-proton-providing surfactant based on the weight of the oil base, and the balance of the emulsion composition being water.

A lavage preservation solution for lung transplantation relates to an organ transplantation technique. According to the scheme provided by the present invention, the lavage fluid contains potassium 3.0-6 mmol / liter, sodium 130-168 mmol / liter, magnesium 1.0-2.5 mmol / liter, chlorine 100-110 mmol / liter, Phosphate 30-40 mmol / L, sulfate 3.5-5.5 mmol / L, prostaglandin E1 108-150 mg / L, raffinose 30-50 mmol / L, low molecular dextran 40 20-38 g / L Lift. The lavage solution can prolong the preservation time of transplanted organs, improve the survival rate of transplanted organs, and preserve the functions of transplanted organs to the greatest extent possible.